2010/06/09

DALACIN

Pharmacological properties: clindamycin phosphate - a semisynthetic antibiotic, clindamycin ester or 7 - (S)-hlorolinkomitsina. Clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of bacterial ribosomes.

In the body of clindamycin phosphate is rapidly hydrolyzed with the formation of clindamycin, which has antibacterial activity.

Clindamycin is active against many gram-positive aerobes and gram-positive and Gram-negative anaerobes. He is active in vitro against microorganisms causing bacterial vaginosis, - Gardnerella vaginalis, Mobiluncus mulieris, Mobiluncus curtisii, Mycoplasma hominis and anaerobes (Peptostreptococcus spr., Bacteroides spr.)

With the introduction of intravaginal suppository (100 mg), 1 time per day exposed to systemic absorption averaged 30% (6,5-70%) of the drug. Systemic effects of clindamycin vaginal application are less pronounced than ingestion or / in the introduction.

INDICATIONS: bacterial vaginosis.

APPLICATION: The recommended dose - 1 suppository intravaginally, preferably at bedtime, for 3 consecutive days.

Suppositories extracted from the packaging before using.

With the introduction of the applicator without the patient in supine position with knees bent and feet pressed against his chest introduces suppository deep into the vagina.

When you enter using the flat end of the suppository applicator is placed in a hole applicator, hold the applicator over the end of the ribbed shell, gently introduce him as deeply as possible into the vagina, slowly pressing the plunger, introduce the suppository and removes the applicator from the vagina. After each use, the applicator should wash with warm soapy water and let it dry completely.

CONTRAINDICATIONS: Hypersensitivity to clindamycin, lincomycin, or other components of the drug.

SIDE EFFECTS: there are less than 10% of cases.

Subject to these side effects: pain in the vagina, vaginal candidiasis, menstrual disorders, vaginal discharge, dysuria, pyelonephritis, vaginitis / vaginal infections, fungal infections, abdominal pain, headache, fever, pain in the side, generalized pain throughout the body localized swelling, candidiasis, nausea, vomiting, diarrhea, itching, rash.

Cautions: Vaginal clindamycin can lead to increased growth insensitive to the antibiotic microorganisms, especially yeasts.

Oral and parenteral use of clindamycin, as well as other antibiotics, may cause the development of diarrhea, and in some cases - colitis. If clindamycin for intravaginal administration develops pronounced or prolonged diarrhea, the drug should be removed and if necessary, assign the appropriate treatment.

Patients should be alert that during treatment should refrain from vaginal intercourse, and not to use the products or funds intended for intravaginal administration (eg tampons, means for the soul).

The product contains components that can reduce the strength of products made of latex or rubber (condoms, diaphragm), so the use of such products during treatment with clindamycin in the form of vaginal suppositories is not recommended.

According to clinical trials Vaginal suppositories with clindamycin phosphate in the II trimester of pregnancy, as well as systemic application of clindamycin in the II-III trimester did not cause any adverse effects.

In the I trimester of pregnancy drug can be used only in the presence of undeniable evidence.

It is not known whether clindamycin is allocated in the breast milk after intravaginal application, so when deciding on the appointment of clindamycin in the form of vaginal suppositories breast-feeding woman is necessary to estimate the ratio of the potential risks and benefits.

INTERACTION: not recommended during treatment with use latex condoms.

When systemic clindamycin phosphate can potentiate the action of blocking the neuromuscular transmission.

OVERDOSE: not described. If you accidentally taking the drug may develop inside the side effects typical of therapeutic concentrations of clindamycin in the blood.

Storage conditions: at 25 ° C, the reach of children.
DALATSIN (DALACIN)


CLINDAMYCINUM G01A A10
Pfizer Inc.

COMPOSITION AND FORM:

TIS. vaginal. 100 mg, № 3 94.17 grn.

Clindamycin 100 mg

Other ingredients: hard fat base Witepsol H-32 (European Pharmacopoeia).

The drug contains clindamycin phosphate in the form.

№ R.03.01/02933 from 23.01.2006 to 23.01.2011

Pharmacological properties: clindamycin phosphate - a semisynthetic antibiotic, clindamycin ester or 7 - (S)-hlorolinkomitsina. Clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of bacterial ribosomes.

In the body of clindamycin phosphate is rapidly hydrolyzed with the formation of clindamycin, which has antibacterial activity.

Clindamycin is active against many gram-positive aerobes and gram-positive and Gram-negative anaerobes. He is active in vitro against microorganisms causing bacterial vaginosis, - Gardnerella vaginalis, Mobiluncus mulieris, Mobiluncus curtisii, Mycoplasma hominis and anaerobes (Peptostreptococcus spr., Bacteroides spr.)

With the introduction of intravaginal suppository (100 mg), 1 time per day exposed to systemic absorption averaged 30% (6,5-70%) of the drug. Systemic effects of clindamycin vaginal application are less pronounced than ingestion or / in the introduction.

INDICATIONS: bacterial vaginosis.

APPLICATION: The recommended dose - 1 suppository intravaginally, preferably at bedtime, for 3 consecutive days.

Suppositories extracted from the packaging before using.

With the introduction of the applicator without the patient in supine position with knees bent and feet pressed against his chest introduces suppository deep into the vagina.

When you enter using the flat end of the suppository applicator is placed in a hole applicator, hold the applicator over the end of the ribbed shell, gently introduce him as deeply as possible into the vagina, slowly pressing the plunger, introduce the suppository and removes the applicator from the vagina. After each use, the applicator should wash with warm soapy water and let it dry completely.

CONTRAINDICATIONS: Hypersensitivity to clindamycin, lincomycin, or other components of the drug.

SIDE EFFECTS: there are less than 10% of cases.

Subject to these side effects: pain in the vagina, vaginal candidiasis, menstrual disorders, vaginal discharge, dysuria, pyelonephritis, vaginitis / vaginal infections, fungal infections, abdominal pain, headache, fever, pain in the side, generalized pain throughout the body localized swelling, candidiasis, nausea, vomiting, diarrhea, itching, rash.

Cautions: Vaginal clindamycin can lead to increased growth insensitive to the antibiotic microorganisms, especially yeasts.

Oral and parenteral use of clindamycin, as well as other antibiotics, may cause the development of diarrhea, and in some cases - colitis. If clindamycin for intravaginal administration develops pronounced or prolonged diarrhea, the drug should be removed and if necessary, assign the appropriate treatment.

Patients should be alert that during treatment should refrain from vaginal intercourse, and not to use the products or funds intended for intravaginal administration (eg tampons, means for the soul).

The product contains components that can reduce the strength of products made of latex or rubber (condoms, diaphragm), so the use of such products during treatment with clindamycin in the form of vaginal suppositories is not recommended.

According to clinical trials Vaginal suppositories with clindamycin phosphate in the II trimester of pregnancy, as well as systemic application of clindamycin in the II-III trimester did not cause any adverse effects.

In the I trimester of pregnancy drug can be used only in the presence of undeniable evidence.

It is not known whether clindamycin is allocated in the breast milk after intravaginal application, so when deciding on the appointment of clindamycin in the form of vaginal suppositories breast-feeding woman is necessary to estimate the ratio of the potential risks and benefits.

INTERACTION: not recommended during treatment with use latex condoms.

When systemic clindamycin phosphate can potentiate the action of blocking the neuromuscular transmission.

OVERDOSE: not described. If you accidentally taking the drug may develop inside the side effects typical of therapeutic concentrations of clindamycin in the blood.

Storage conditions: at 25 ° C, the reach of children.